BioNTech Results Presentation Deck
2 BNT122 iNeST randomized Phase 2 trials ongoing and planned
Study Design
and Patient
Population
13
Rationale
Status
First-Line Advanced Melanoma
A Phase 2, open-label, multicenter
randomized trial of the efficacy and
safety of BNT122 in combination with
pembrolizumab vs. pembrolizumab in
patients with previously untreated
Advanced Melanoma
●
Evaluate added benefit of 1L
BNT122 in an advanced CPI-
sensitive tumor (PFS, ORR)
Success ungates 1L use of iNeST
in CPI-sensitive advanced
cancers for combination therapy
Enrollment update in
2H 2020
●
Adjuvant Non-Small Cell Lung
Cancer
A Phase 2, open-label, multicenter,
randomized trial of the efficacy and safety of
BNT122 in combination with atezolizumab
vs. atezolizumab alone following adjuvant
platinum-doublet chemotherapy in patients
who are ctDNA positive after surgical
resection of Stage II-III NSCLC
Evaluate added benefit of BNT122
in a micrometastatic CPI-sensitive
tumor (RFS)
Success ungates adjuvant use of
iNeST in CPI-sensitive ctDNA+
cancer types
To start in 2H 2020
●
Adjuvant Colorectal Cancer
A Phase 2, open-label, multicenter
randomized trial to compare the efficacy
of BNT122 versus watchful waiting in
patients with ctDNA positive, surgically
resected Stage 2/3 rectal cancer, or
Stage 2 high risk/stage 3 colon cancer
Evaluate added benefit of
BNT122 in a micrometastatic
CPI-insensitive tumor (RFS)
Success ungates adjuvant use of
iNeST for CPI-insensitive ctDNA+
cancer types
To start in 2H 2020
BIONTECHView entire presentation